Weekly Digests
‹ Back to November

Rotavirus vaccine and anti-CTLA-4: a dynamic duo

November 20, 2019

Aiming to increase the number of patients, particularly pediatric patients, who respond to immune checkpoint blockade (ICB), Shekarian et al. explored whether existing anti-infectious disease vaccines could be used to increase the immunogenicity of tumors and overcome resistance to ICB. The results, recently published in Science Translational Medicine, suggest that the clinical-grade rotavirus vaccines possess both immunostimulatory and oncolytic functions, and could potentially be quickly translated to the clinic in the context of cancer immunotherapy.

The researchers chose to pursue anti-infectious disease vaccines because they contain pathogens that trigger pattern recognition receptors (PRRs) – including Toll-like receptors (TLRs) – and could act as PRR agonists to prime an immune response. Evaluation of 14 viral and bacterial vaccines via incubation with transgenic HEK-293T cell lines expressing different TLRs revealed that the Mycobacterium tuberculosis vaccine (BCG) activated TLR2 and the typhoid fever vaccine (Tyavax) activated TLR4, as indicated by NF-κB induction. Surprisingly, the two rotavirus vaccines (Rotarix and Rotateq), when administered at mid-range concentrations, activated NF-κB in all transgenic cell lines, including the parental 293T cell line that did not express any TLRs, suggesting that the activation was independent of any TLR. At high concentrations, rotavirus vaccines reduced the viability of the 293T cells.

Next, the researchers evaluated in vivo antitumor properties of the four NF-κB-activating vaccines in a mouse model of neuroblastoma (Neuro2a) that is resistant to ICB monotherapies (anti-PD-1, anti-PD-L1, anti-CTLA-4) and their combinations. Intratumoral injections of Tyavax and BCG did not lead to any antitumor activity. In contrast, intratumoral injections of rotavirus vaccines led to tumor rejection in 40% of mice and a significant survival benefit. In mice with A20 B cell lymphoma, rotavirus led to tumor regressions in 70% of mice and complete cures in more than 50% of mice. In the NXS2 neuroblastoma model, rotavirus slowed tumor growth in some mice but did not significantly impact survival.

Exploring the mechanism behind the rotavirus-induced antitumor response, Shekarian et al. observed that in vitro, the rotavirus vaccines were cytotoxic against numerous human and mouse cancer cell lines in a dose-dependent manner (albeit less potently in mice), and were preferentially cytotoxic against cancer cells versus healthy cells, suggesting that the rotavirus was an oncolytic virus. When the rotavirus was inactivated with heat and UV irradiation, cytotoxicity was lost in vitro. Transcriptomic analysis of various tumor cell types exposed in vitro to active or inactivated rotavirus revealed six commonly upregulated genes, including interferon regulatory factor 7 (Irf7), CD274 (encoding PD-L1), and Ddx58 (encoding the double-stranded RNA sensor retinoic acid-inducible gene I, RIG-I). Notably, rotavirus also activated human monocyte-derived macrophages from healthy donors, even when the rotavirus was inactivated.

In vivo, as early as 24 hours after intratumoral injection, rotavirus treatment led to a rapid increase in the percentage of intratumoral CD11b+ myeloid cells, but did not affect the proportions of CD4+ T cells, CD8+ T cells, or Tregs. Active, but not inactivated, rotavirus upregulated the costimulatory molecules CD80 and CD86 in murine tumors, particularly on myeloid cells. A significant proportion of CD8+ T cells also had upregulated activation markers. CTLA-4 was upregulated on CD8+ T cells and Tregs. Rotavirus also induced immunogenic cell death in human and murine cancer cell lines, as indicated by the extracellular release of ATP. Genes commonly upregulated in vivo by both active and inactive rotavirus included type I IFN pathway genes, Ifng, T effector genes (e.g. IL-25, IL-9, IL-17, Tbet), and retinoic acid binding-related orphan receptor c (RORc). Together, the in vitro and in vivo data show that the rotavirus, whether active or inactivated, triggers a coordinated antitumor immune response.

Mechanistic data provided the rationale for testing intratumoral injection of rotavirus in combination with systemic anti-CTLA-4. In the Neuro2a model, which was resistant to anti-CTLA-4 and partially responsive to rotavirus, the combination treatment synergized to achieve a 100% complete response rate with no relapse. Similar efficacy was observed in the A20, EMT6, and CT26 (colon carcinoma) tumor models. Importantly, intratumoral delivery of rotavirus was required for the synergistic effect, as systemic delivery had very little antitumor effect, both alone and in combination with anti-CTLA-4. Since rotavirus led to upregulation of PD-L1 on cancer cells, the researchers also tested the combination of intratumoral injection of the rotavirus and systemic injection of anti-PD-L1 and found that it resulted in a 100% cure rate in the A20 tumor model.

Next, the researchers asked whether the rotavirus-mediated antitumor responses were primarily due to direct oncolytic or immune-mediated effects. In the immunodeficient NSG mice bearing Neuro2a tumors, the rotavirus-mediated antitumor response was completely abolished. Surprisingly, while the inactivated rotavirus elicited no antitumor response in wild-type mice as a monotherapy, it synergized with and overcame resistance to anti-CTLA-4 with a similar efficacy to the active rotavirus. Depletion experiments demonstrated that CD8+ T cells were absolutely required for the antitumor effect of rotavirus monotherapy and combination with anti-CTLA-4. CD4+ T cells and NK cells also contributed to the antitumor response. CD8+ T cells had upregulated IFNγ production and upregulated surface activation markers (e.g. CD137, OX40) after combination treatment. The combination therapy induced a systemic antitumor response and led to the formation of long-term, tumor-specific immunological memory in cured mice and the ability to control both injected and abscopal tumors. Furthermore, preimmunization with the rotavirus vaccine did not impact the synergistic antitumor effect of the combination therapy in mice. Thus, although direct oncolytic effects could be present, rotavirus-mediated antitumor effect involved the engagement of various immune cells.

Altogether, Shekarian et al. demonstrated that rotavirus vaccines synergized with and overcame resistance to anti-CTLA-4 in several cancer models, including those common in pediatric patients. As rotavirus vaccines are clinically used in pediatric patients, they could potentially be quickly translated to the clinic as a source of an oncolytic virus and tested in combination with approved checkpoint blockade immunotherapies.

by Anna Scherer


Shekarian T., Sivado E., Jallas A.C., Depil S., Kielbassa J., Janoueix-Lerosey I., Hutter G., Goutagny N., Bergeron C., Viari A., Valsesia-Wittmann S., Caux C., Marabelle A. Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. Sci Transl Med. 2019 Oct 23.

In the Spotlight...

Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR

To delineate the relative contribution of multiple HLA alleles to peptide editing by the intracellular MHC chaperone TAPBPR, Ilca et al. evaluated TAPBPR binding to HLA on beads and on cell surfaces, peptide editing on cellular surfaces, and binding/editing of targeted HLA mutations. HLA-A, in particular HLA-A2 and -A24 supertypes, were significantly more impacted by TAPBPR than HLA-B/C or other HLA-A family members. This preferential binding/editing was strongly associated with H114 and Y116 in the anchor residue binding F pocket of HLA. Allele-specific preferential editing may have implications for sensitivity to disease.

XCL1/glypican-3 fusion gene immunization generates potent antitumor cellular immunity and enhances anti-PD1 efficacy

To improve immunotherapy for hepatocellular carcinoma (HCC), Chen et al. fused the dendritic cell (DC) chemokine XCL1 to glypican-3 (GPC3) that is specific for malignant hepatocytes. Cells expressing XCL1-GPC3 chemoattracted XCR1+ mouse CD8α+ and human CD141+ DCs in vitro and increased IL-12 levels. Immunization with mXcl1-GPC3 plasmid in a liver model before or after tumors had formed significantly inhibited tumor growth and increased GPC3-specific CD8+ T cell infiltration as well as IFNγ and GRZB levels; this effect was augmented by anti-PD-1. Similar results were obtained in HCC-PDX models using autologous DC-stimulated T cells.

Contributed by Katherine Turner

Multiple cancer-specific antigens are targeted by a chimeric antibody receptor on a single cancer cell

He et al. generated CAR T cells (237CART) with the binding domain of the 237 antibody (237Ab) which recognizes an aberrantly O-glycosylated murine podoplanin (Tn-PDPN). In a mouse leukemia model, Tn-PDPN-expressing Jurkat cells were eradicated by 237CART cells. Unexpectedly, native Jurkat cells also were eradicated. In vitro, native Jurkat cells and other COSMC- cells that didn’t bind 237Ab but expressed Tn-MUC1 or other Tn-glycosylated proteins were lysed by 237CART cells. Reactivity with multiple Tn-glycosylated proteins (expressed only on cancer cells) identify 237CART cells as a promising candidate to treat Tn-expressing tumors.

Contributed by Samuel Goldman

VISTA is an acidic pH-selective ligand for PSGL-1

Johnston et al. investigated the function of VISTA, a B7 family ligand expressed on myeloid cells and at low levels on activated T cells. The ligand for VISTA was identified as PSGL-1, which it bound under acidic conditions, mediated by histidine residues on the VISTA extracellular domain. VISTA acted as a co-inhibitor of T cells at an acidic pH, reminiscent of the TME, suppressing proliferation, IFNγ production, and NF-κB phosphorylation. VISTA-blocking antibodies, which were also pH sensitive, restored T cell responsiveness and, when combined with anti-PD-1, increased T cell infiltration and enhanced antitumor efficacy in MC38-bearing mice.

Antigen-loaded monocyte administration induces potent therapeutic anti-tumor T cell responses

Despite weak antigen (Ag) uptake by monocytes, Huang et al. show that protein- or MHC-I-restricted-peptide-Ag- loaded undifferentiated monocytes injected IV induced stronger antitumor activity than DC-, protein/adjuvant-, or tumor cell- based vaccines in two aggressive murine tumor models. Cell contact-dependent connexin 43-containing gap junction formation, but not phago- or trogo- cytosis, was required for Ag transfer from monocytes to splenic white pulp (but not lymph node) CD8+ cDCs, which then cross-primed naive CD8+ T cells to become potent cytolytic cells. DCs were also required for monocyte Ag activation of human T cells in vitro.

Contributed by Paula Hochman

OPINION: Peptide Channeling: The Key to MHC Class I Immunosurveillance

Yewdell et al. summarize multiple sources of data and speculate on a fundamental question of adaptive immunity – how does the antigen processing machinery of the cell efficiently distinguish and highlight new and potentially dangerous genetic information from the vast extant transcriptome/proteome of the cell? Drawing on known examples of non-canonical translation and peptide presentation (CUG initiation, UTR and lncRNA open reading frames, nuclear translation), DRiPs, ribosome alterations, and examples of formation of compartmentalized cell “organelles”, Yewdell et al. synthesize testable hypotheses and pose key outstanding questions.

Everything New this Week In...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.